Diagnosis and Management of Borrelia Infection
Clinical Diagnosis
- Clinical diagnosis of Borrelia infection is sufficient without laboratory confirmation when classic Erythema Migrans (EM) is present in an endemic area, where EM is defined as a gradually expanding annular lesion >5 cm in diameter, and approximately 70-80% of persons with Lyme disease have EM 1, 2, 3
- Detailed history and physical examination are essential, and most patients will have EM, which is sufficient for diagnosis and immediate treatment without laboratory confirmation, as recommended by the American College of Rheumatology and the IDSA 1, 2
- If classic erythema migrans is present in an endemic area, treat empirically without waiting for serologic confirmation, according to the CDC guidelines 1
Serological Testing
- The diagnosis of Borrelia infection requires a two-tiered serological testing approach, starting with a screening ELISA or IFA followed by confirmatory Western blot, with direct detection methods reserved for specific clinical scenarios 4
- First-tier screening tests can be either Enzyme-linked immunosorbent assay (ELISA) or indirect fluorescent antibody test (IFA), with results reported as positive, negative, or equivocal/borderline, and a sensitivity ranging from 85-100% and specificity around 79-95% depending on the assay 5, 1, 6, 7
- The two-EIA approach, using whole-cell sonicate EIA followed by C6 EIA, shows higher sensitivity for early Lyme disease (61% vs. 48%) with equivalent specificity (99.5%) compared to standard two-tiered testing, as recommended by the American College of Physicians 1
- Interpretation criteria for Western Blot are as follows:
| Test | Interpretation Criteria |
|---|---|
| IgM Western Blot | ≥2 of 3 specific bands (21-24, 39, 41 kDa) |
| IgG Western Blot | ≥5 of 10 specific bands (18, 21-24, 28, 30, 39, 41, 45, 58, 66, 93 kDa) |
- The second-tier confirmatory test is the Western immunoblot (WB) test, which is only performed when the first-tier test is positive or equivocal, and has a specificity of >95% across all stages, as stated by the American College of Physicians 5, 1
Direct Detection Methods
- Diagnosis of Borrelia infection is primarily by direct detection of spirochetes in blood during febrile episodes 4
- Direct visualization of spirochetes in peripheral blood during febrile episodes has a sensitivity of approximately 70% using dark-field microscopy or Giemsa/Wright stain 4
- Culture attempts should only be performed in reference laboratories and in specific clinical circumstances, such as atypical erythema migrans or suspected neuroborreliosis without detection of intrathecal antibodies, as recommended by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 4
Laboratory Testing
- Culture has limited utility due to low sensitivity and technical difficulty, but has a highest yield from skin biopsy of EM lesions (50-70% sensitivity) 4
- PCR is useful for synovial fluid in suspected Lyme arthritis (50-70% sensitivity) and has low sensitivity in CSF (10-30%) 4
- PCR of CSF has low sensitivity (10-30%) for diagnosing Neuroborreliosis 4
- PCR testing of synovial fluid may be useful for suspected Lyme arthritis (sensitivity >75%), as stated by the American Academy of Pediatrics and the CDC guidelines 1
- Intrathecal antibody testing is helpful in suspected neuroborreliosis, particularly in regions with high seroprevalence, according to the Clinical Infectious Diseases journal and the IDSA 1
Treatment and Management
- The American College of Rheumatology recommends that treatment should be initiated immediately upon clinical diagnosis of erythema migrans without waiting for laboratory confirmation, and oral antibiotic therapy for 28 days is recommended for patients with Lyme arthritis 2
- Additional antibiotic therapy is not recommended for persistent or recurring nonspecific symptoms following recommended treatment, as stated by the American College of Physicians and the IDSA 8
- Persistent symptoms after treatment do not respond to long-term antibiotic therapy based on randomized-controlled trial data, according to the Clinical Infectious Diseases journal 9
- Early antibiotic treatment can blunt or prevent antibody response, and consider follow-up testing in 2-3 weeks if symptoms persist and clinical suspicion remains high, according to the Infectious Diseases Society of America 4
- Routine testing is not recommended for patients with typical amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, dementia, new-onset seizures, or psychiatric illness, as stated by the American College of Rheumatology and the American College of Physicians 2